On the 6Thursday On September 2022, Azerbaijan Thalassemia Center and BGI held a virtual signing ceremony to conclude a cooperation agreement. The partnership aims to improve thalassemia screening in Azerbaijan through genetic technology.
In early 2021, on the occasion of the “Prevention and Control of Global Hemoglobinopathies” announcement, the BGI Panel on Poverty Prevention and Control made it clear that it seeks to export China’s advanced thalassemia technologies to the “Belt and Road Initiative” countries to jointly achieve comprehensive thalassemia control . in the global community.
In April 2022, BGI’s wholly-owned subsidiary, Huada Biotechnology (Wuhan) Co., Ltd, received a medical device registration certificate from the National Drug Administration for its alpha and beta thalassemia gene detection kit (combining a probe-anchored polymerase sequencing method).
This agreement was signed by Dr. Valeh Huseynov, executive director of the National Hematology and Transfusion Center, Dr. Agha Rza Aghayev, Head of Azerbaijan Department of Medical Genetics, and Mr. Jeremy Cao, Vice President of BGI IntDx. The two organizations have entered into a strategic partnership and will collaborate on a thalassemia research project in the country.
Dr Agha Rza Aghayev, head of the Department of Medical Genetics in Azerbaijan, said the following: “Thank you BGI for your support and cooperation, I hope this research program will help us build an efficient and well-designed method for thalassemia screening.”
Azerbaijan is one of the countries with the highest prevalence rate of thalassemia. Our thalassemia gene detection testing combines a state-of-the-art high-throughput sequencing platform with the advantages of low cost and comprehensive detection. It helps the scientific-research partnership in methodological comparison, improves cooperation of new technologies in clinical testing and investigation of thalassemia screening in Azerbaijan. BGI also has the World Hemoglobinopathy Foundation which focuses on the global fight against thalassemia, our aim is to make the world a better place without this disease. BGI is therefore proposing this agreement to reaffirm that we stand with the Azerbaijan Thalassemia Center and its people.”
Zhiyu Peng, vice president of BGI Genomics
Mr. Jeremy Cao, Vice President of BGI IntDx, said at the signing ceremony: “This is one of our pioneering overseas thalassemia projects, and such an agreement commits us to closer cooperation on the common goals of thalassemia surveillance and control. and a vision that in the not-too-distant future the world will be free of this disease. I would like to say that I am sure that with our efforts and determination we will be able to achieve more and continue to develop even stronger relations and friendship between the people of Azerbaijan and BGI.”
Thalassemia, an inherited blood disorder, caused by insufficient production of hemoglobin in red blood cells, which carry oxygen and nutrients to all parts of the body. People with thalassemia have much less hemoglobin than normal people and usually suffer from mild to severe anemia.
The Azerbaijan Thalassemia Center is the main leading public health facility fighting thalassemia in the region. This center provides services not only to patients with this disease, but also to people with other genetic diseases. The country also offers a foundation providing health services to foreigners in this center.
#Azerbaijan #Thalassemia #Center #BGI #Partner #Improve #Thalassemia #Screening #Azerbaijan